Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 30 of 32 for:    Recruiting, Not yet recruiting, Available Studies | obesity | stimulation

In Vitro Fertilization Impact on Metabolic Parameters (IVF)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03426228
Recruitment Status : Recruiting
First Posted : February 8, 2018
Last Update Posted : May 9, 2019
Sponsor:
Collaborators:
Fakih IVF Fertility Center
University of Sharjah
Information provided by (Responsible Party):
Ayla Coussa, University of Warwick

Brief Summary:
A quantitative prospective cohort study will be conducted, where blood samples will be collected at different timings during the IVF protocol, to assess the impact of fertility medications on metabolic parameters of patients undergoing IVF treatment.

Condition or disease Intervention/treatment
GDM Insulin Resistance Glucose Intolerance PCOS Obesity Diagnostic Test: HbA1C

Detailed Description:

Numerous factors predispose women to develop pregnancy-related complications, these include gestational diabetes (GDM), pre-pregnancy obesity, advanced maternal age (> 35 years) and gestational age, abnormal weight gain during pregnancy, family history of diabetes, PCOS and low parity. Evidenced-based studies reported that women with PCOS have a significantly higher risk of developing GDM compared with women without PCOS, independently of the obesity factor; this risk is higher when both factors coexist.

Given the known effect of reproductive hormones on weight-gain, controversies still exist on whether ART predispose women to more adverse obstetric outcomes compared to normal pregnancy. ART describes different procedures to help women become pregnant, with In Vitro Fertilization (IVF) being the most commonly performed. It has been demonstrated that IVF is associated with glucose intolerance in mice and it will be interesting to determine whether this physiologic phenomenon is also altered by IVF medication (such as estrogen and progesterone) in humans. While some studies reported that singleton pregnancies conceived by ART (IVF or ovulation induction) were strongly associated with GDM compared to spontaneous conceptions, other studies did not find significant differences in the risk of GDM. Increased GDM risk presented with IVF can be associated with prenatal obesity or secondary to maternal PCOS condition. The former studies did not specify the body mass index (BMI) and the medical history of participants undergoing IVF, such as the presence of PCOS. Due to limited available data, we still cannot distinguish whether these adverse pregnancy outcomes are due to the pre-existing conditions such as PCOS, or are secondary to the IVF therapy itself.


Layout table for study information
Study Type : Observational [Patient Registry]
Estimated Enrollment : 192 participants
Observational Model: Cohort
Time Perspective: Prospective
Target Follow-Up Duration: 9 Months
Official Title: Effects of Fertility Drugs on Glucose Homeostasis and Other Metabolic Parameters on Patients Undergoing In Vitro Fertilization (IVF)
Actual Study Start Date : February 15, 2018
Estimated Primary Completion Date : September 1, 2019
Estimated Study Completion Date : December 31, 2019

Intervention Details:
  • Diagnostic Test: HbA1C

    After overnight fasting, 10 ml of blood will be collected at four different timings during the IVF protocol:

    1. At baseline (second day of the menstrual period)
    2. Triggering phase (post-egg retrieval procedure)
    3. Embryo transfer phase (post-transfer procedure)
    4. Week 4 (positive bHCG)

    4. Week 8 of pregnancy

    Other Names:
    • Lipid profile
    • Hormonal profile: FSH, LH, progesterone, estrogen,Beta-HCG
    • Serum Insulin level
    • Fasting Glucose level
    • Thyroid-Stimulating Hormone


Primary Outcome Measures :
  1. Short-term effect of fertility medications on glucose homeostasis and insulin resistance in patients undergoing IVF treatment [ Time Frame: 8 weeks of pregnancy ]
    Participants who experience an abnormal increase in fasting glucose (>110) and A1C (>5.7) will be identified post-treatment. Also, for those previously known to be insulin-resistant, HOMA ratio will help identifying whether the treatment worsens or has no effect on their insulin resistance state.


Secondary Outcome Measures :
  1. Effect of fertility medications on other metabolic parameters [ Time Frame: 8 weeks of pregnancy ]
    Lipid profile will be measured before and after treatment; participants experiencing hypercholesterolemia post-treatment will be consulted by a dietitian to help them better manage the condition during their pregnancy (total chol, LDL and triglycerides)

  2. Effect of fertility medications on thyroid function [ Time Frame: 8 weeks of pregnancy ]
    TSH level will be measured pre- and post-IVF. Early diagnosis of thyroid dysfunction will be closely monitored with frequent repetitions of blood test, especially during the first trimester.


Other Outcome Measures:
  1. Long-term effect of fertility medications in relation to maternal and fetal outcomes [ Time Frame: 9 months of pregnancy ]
    Early management and/control of metabolic-related adverse outcomes in relation to IVF treatment will prevent GDM by for instance glucophage administration or regular blood test of TSH for participants reported to be at higher risk of thyroid dysfunction.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 39 Years   (Adult)
Sexes Eligible for Study:   Female
Gender Based Eligibility:   Yes
Gender Eligibility Description:   We will have two main groups of: Obese (BMI: 30-38) and non-obese (BMI: 18.5-29.9) women with the following criteria
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
A convenience sample from adult women of < 39 years of age undergoing fresh IVF treatment at Fakih IVF Clinic in Dubai will be chosen. Participants who will fulfill the inclusion criteria will be recruited.
Criteria

Any patient presenting to us for fresh IVF with the following:

Inclusion Criteria:

  • Presenting with or without PCOS
  • Presenting with structural or mechanical infertility, such as fallopian tube obstruction, endometriosis, fibroids
  • Presenting with male factor
  • Presenting with or without insulin resistance
  • Combination of more than one of the listed above criteria

Exclusion Criteria:

  • Pre-diabetes or diabetes patients (confirmed by impaired or abnormal OGTT)
  • Age above 39 years of age
  • Taking glucose-lowering meds, such as metformin or janumet.
  • Taking corticosteroids

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03426228


Contacts
Layout table for location contacts
Contact: Thomas Barber, MD 00447808503749 T.Barber@warwick.ac.uk
Contact: Haydar Hasan, MD 00971504979215 haidarah@sharjah.ac.ae

Locations
Layout table for location information
United Arab Emirates
Fakih IVF Recruiting
Dubai, United Arab Emirates, 72960
Contact: Ayla Coussa, Dietitian    00971 4 349 7600 ext 162    a.coussa@warwick.ac.uk   
Contact: Michael Fakih, MD    00971 4 349 7600 ext 117    mfakih@fakihivf.com   
Sponsors and Collaborators
University of Warwick
Fakih IVF Fertility Center
University of Sharjah
Investigators
Layout table for investigator information
Principal Investigator: Ayla Coussa, Dietitian Fakih IVF Dubai

Additional Information:

Layout table for additonal information
Responsible Party: Ayla Coussa, MSc., University of Warwick
ClinicalTrials.gov Identifier: NCT03426228     History of Changes
Other Study ID Numbers: DSREC-11/2017_09
First Posted: February 8, 2018    Key Record Dates
Last Update Posted: May 9, 2019
Last Verified: May 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: All the study information will be kept confidential. Patients' names will not be identified in any publication or presentation of the study findings. Only groups' results will be reported.
Supporting Materials: Study Protocol
Statistical Analysis Plan (SAP)
Informed Consent Form (ICF)
Clinical Study Report (CSR)
Analytic Code
Time Frame: After conducting data collection and analysis the results will be available upon official publication.
Access Criteria: Data access requests will be reviewed by an external independent committee. Requestors will be required to sign a Data Access Agreement.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Ayla Coussa, University of Warwick:
IVF, Glucose Homeostasis, Metabolic Parameters
Additional relevant MeSH terms:
Layout table for MeSH terms
Insulin Resistance
Glucose Intolerance
Hyperinsulinism
Glucose Metabolism Disorders
Metabolic Diseases
Hyperglycemia
Progesterone
Progestins
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs